Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Evidence gaps in advanced cancer care: community-based clinicians' perspectives and priorities for comparative effectiveness research.

Lowry SJ, Loggers ET, Bowles EJ, Wagner EH.

J Oncol Pract. 2012 May;8(3 Suppl):28s-33s. doi: 10.1200/JOP.2012.000569.

2.

Evidence gaps in advanced cancer care: community-based clinicians' perspectives and priorities for CER.

Lowry SJ, Loggers ET, Bowles EJ, Wagner EH.

Am J Manag Care. 2012 May;18(5 Spec No. 2):SP77-83.

3.

A tall order on a tight timeframe: stakeholder perspectives on comparative effectiveness research using electronic clinical data.

Holve E, Lopez MH, Scott L, Segal C.

J Comp Eff Res. 2012 Sep;1(5):441-51. doi: 10.2217/cer.12.47.

PMID:
24236421
4.

Health care decision makers' use of comparative effectiveness research: report from a series of focus groups.

Villa L, Warholak TL, Hines LE, Taylor AM, Brown M, Hurwitz J, Brixner D, Malone DC.

J Manag Care Pharm. 2013 Nov-Dec;19(9):745-54.

5.

Evaluating Comparative Effectiveness Research Priorities for Care Coordination in Chronic Obstructive Pulmonary Disease: A Community-Based eDelphi Study.

Stellefson M, Alber J, Paige S, Castro D, Singh B.

JMIR Res Protoc. 2015 Aug 12;4(3):e103. doi: 10.2196/resprot.4591.

6.
7.

Comparative effectiveness research (CER): a summary of AHRQ's CER on therapies for rheumatoid arthritis.

Oderda GM, Balfe LM.

J Manag Care Pharm. 2011 Nov-Dec;17(9 Suppl B):S19-24.

8.
9.

Got CER? Educating Pharmacists for Practice in the Future: New Tools for New Challenges.

Perfetto EM, Anyanwu C, Pickering MK, Zaghab RW, Graff JS, Eichelberger B.

J Manag Care Spec Pharm. 2016 Jun;22(6):609-16. doi: 10.18553/jmcp.2016.22.6.609.

10.

Evaluation of Pharmacy and Therapeutic (P&T) Committee member knowledge, attitudes and ability regarding the use of comparative effectiveness research (CER) in health care decision-making.

Tang DH, Warholak TL, Hines LE, Hurwitz J, Brown M, Taylor AM, Brixner D, Malone DC.

Res Social Adm Pharm. 2014 Sep-Oct;10(5):768-80. doi: 10.1016/j.sapharm.2013.11.008.

PMID:
24480384
11.

Can CER be an effective tool for change in the development and assessment of new drugs and technologies?

Brixner DI, Watkins JB.

J Manag Care Pharm. 2012 Jun;18(5 Supp A):S06-11.

PMID:
22663293
12.

Evidence Brief: The Quality of Care Provided by Advanced Practice Nurses.

McCleery E, Christensen V, Peterson K, Humphrey L, Helfand M.

VA Evidence-based Synthesis Program Evidence Briefs [Internet]. Washington (DC): Department of Veterans Affairs (US); 2011-.
2014 Sep.

13.
14.

Some methodological points to consider when performing systematic reviews in comparative effectiveness research.

Berlin JA, Cepeda MS.

Clin Trials. 2012 Feb;9(1):27-34. doi: 10.1177/1740774511427062.

PMID:
22049086
16.
17.

US Payer Perspectives on Evidence for Formulary Decision Making.

Wang A, Halbert RJ, Baerwaldt T, Nordyke RJ.

J Oncol Pract. 2012 May;8(3 Suppl):22s-7s. doi: 10.1200/JOP.2011.000526.

18.

Methods in comparative effectiveness research.

Armstrong K.

J Clin Oncol. 2012 Dec 1;30(34):4208-14. doi: 10.1200/JCO.2012.42.2659. Review.

19.

International comparison of comparative effectiveness research in five jurisdictions: insights for the US.

Levy AR, Mitton C, Johnston KM, Harrigan B, Briggs AH.

Pharmacoeconomics. 2010;28(10):813-30. doi: 10.2165/11536150-000000000-00000. Review.

PMID:
20831289
20.

Prioritizing comparative effectiveness research for cancer diagnostics using a regional stakeholder approach.

Klein G, Gold LS, Sullivan SD, Buist DS, Ramsey S, Kreizenbeck K, Snell K, Loggers ET, Gifford J, Watkins JB, Kessler L.

J Comp Eff Res. 2012 May;1(3):241-55.

Items per page

Supplemental Content

Support Center